ADIM
ACLS icon

Alpha DNA Investment Management’s Axcelis ACLS Stock Holding History

Alpha DNA Investment Management’s Portfolio ACLS Stock Details ACLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,528
Closed -$516K – 150
2022
Q3 		$516K Buy
+8,528
New +$551K 0.43% 126
2022
Q2 		– Sell
-15,958
Closed -$1.2M – 117
2022
Q1 		$1.2M Sell
15,958
-6,032
-27% -$412K 0.85% 65
2021
Q4 		$1.64M Sell
21,990
-7,533
-26% -$446K 1.03% 31
2021
Q3 		$1.39M Buy
+29,523
New +$1.28M 0.94% 64

Other funds holding ACLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Alpha DNA Investment Management's ACLS Position: Q4 2022 in Review

Alpha DNA Investment Management sold out of Axcelis (ACLS) in Q4 2022, closing a stake of 8,528 shares — an estimated $516K sold.

Alpha DNA Investment Management first reported a position in ACLS in Q3 2021 and held it in 4 quarters. The position peaked at $1.64M in Q4 2021. 325 funds tracked by Wall St. Rank hold ACLS as of Q4 2022.

  • Alpha DNA Investment Management reported no remaining Axcelis position as of Q4 2022 after selling out during the quarter.
  • Alpha DNA Investment Management sold 8,528 Axcelis shares in Q4 2022, an estimated $516K.
  • Alpha DNA Investment Management first reported a position in Axcelis in Q3 2021 and held it in 4 quarters.
  • Alpha DNA Investment Management's Axcelis position peaked at $1.64M in Q4 2021.
  • 325 funds tracked by Wall St. Rank held Axcelis as of Q4 2022.

Based on Alpha DNA Investment Management's 13F filing for Q4 2022, filed 27 Jan 2023.